Caribou Biosciences has stopped work on its two top allogeneic CAR T cell therapy programs. The company is now starting a full strategic review. This is a sharp turn for the CRISPR genome-editing firm. Vispacabtagene regedleucel (vispa-cel) and CB-011 were its main hopes for bringing cell therapies to patients with tough cancers. That changed this week.
In the CaMMouflage phase I trial, CB-011 achieved an overall response rate of 92% among 12 BCMA-naïve multiple myeloma patients, with 83% reaching complete or stringent complete response and 91% of evaluable patients being MRD-negative.
Strategic review and immediate impact
The board has approved a full review of options. These include a merger, acquisition, or other business deals involving Caribou or its assets. Wedbush Securities Inc. is the exclusive financial advisor for this process. There is no set timeline. Caribou says it will only update the public if a clear decision is made or if disclosure is required.
The fallout is swift. Caribou will cut jobs and costs across the company. Most layoffs are expected to finish in the fourth quarter of 2026. As of June 30, 2026, Caribou had $113.8 million in cash, cash equivalents, and marketable securities. That money is now set aside for the review and restructuring. The cuts are deep.
Pipeline and scientific background
Vispacabtagene regedleucel (vispa-cel), once called CB-010, is an allogeneic anti-CD19 CAR T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma. Caribou says it is the first allogeneic CAR T therapy in the clinic with a PD-1 knockout. This genome-editing step is meant to prevent early CAR T cell exhaustion. The FDA has given vispa-cel Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug status for B-NHL. In trials, vispa-cel has shown safety, efficacy, and durability similar to autologous CAR T therapies.
A key unresolved issue for CB-011 remains the durability of response, comparison with autologous CAR-T products, and long-term safety; the small sample size of 12 patients does not yet allow for conclusions about efficacy in a broader population.
Both programs use Caribou’s chRDNA genome-editing technology. The goal is to make cell therapies with better precision and stronger disease-fighting power. Caribou’s decision to stop these programs stands out. Other companies, like CRISPR Therapeutics, have shown recent progress in gene-edited CAR T cell therapy, as reported earlier.
Editorial view
Caribou’s exit from its lead allogeneic CAR T cell programs is a clear sign of the financial pressure on even the most advanced cell therapy developers. The company is shelving phase 3-ready and FDA-designated assets. That says a lot. Science alone is not enough when capital is tight. The sector is now watching Caribou’s strategic review. It will test if the market still wants high-risk, high-reward cell therapy innovation. The future depends on more than clinical data. Funding and operational strength are now just as important.
